サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1424107

多発性硬化症市場、シェア、規模、動向、産業分析レポート：薬剤タイプ別、投与経路別、地域別、セグメント別予測、2024年～2032年

Multiple Sclerosis Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Immunosuppressants, Immunomodulators); By Route of Administration; By Region; Segment Forecast, 2024 - 2032
出版日: | 発行: Polaris Market Research | ページ情報: 英文 119 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
多発性硬化症市場、シェア、規模、動向、産業分析レポート：薬剤タイプ別、投与経路別、地域別、セグメント別予測、2024年～2032年
出版日: 2024年01月24日
発行: Polaris Market Research
ページ情報: 英文 119 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界の多発性硬化症市場規模は2032年までに335億7,000万米ドルに達する見込みです。本レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

著名な市場参入企業が画期的な医薬品を生み出すために研究開発（R&D）を重視するようになったことが、世界市場の拡大につながっています。例えば、Adamas Pharmaceuticals Inc.は2020年12月、多発性硬化症（MS）患者を治療するために設計された治験中のアマンタジン製剤ADS-5102を評価する第3相臨床試験の結果を発表しました。

製品のイントロダクション、治療とケアへのアクセス向上のための政府の取り組みのエスカレート、多発性硬化症の罹患率の上昇が市場の成長を促進すると予想されます。

多発性硬化症の世界の影響の増大は、ヘルスケアプロバイダーや政府の懸念を増大させています。この疾患の有病率の上昇により、多くの国々の政府はガイドラインや勧告の策定などの積極的な対策を講じざるを得なくなっています。

また、政府機関は、利用可能な様々な治療オプションについて患者を教育するために、様々な啓発キャンペーンを開始しています。

例えば、ドイツ多発性硬化症協会は、多発性硬化症患者を支援するために、ドイツ国内で3～4つの業界を運営しています。彼らは、多発性硬化症に罹患した人々のために、アクセシビリティの障壁を取り除き、サポートネットワークを拡大することを目的として、毎年5月31日に世界MSデー大会を開催しています。

多発性硬化症の治療において、モノクローナル抗体が普及してきています。多くの企業が、これらの抗体の可能性を活用した多発性硬化症の新薬開発に取り組んでいます。さらに、多発性硬化症の治療に用いられる免疫抑制剤の一般的なクラスであるヒト化モノクローナル抗体の世界の需要が増加しています。特に、F. Hoffmann-La Roche Ltd.から発売されたOcrevusは、最大の医薬品として台頭し、多額の収益に貢献し、市場の継続的な成長に寄与しています。

多発性硬化症市場レポートハイライト

多発性硬化症市場では、免疫調節薬分野が最大の売上シェアを占めています。免疫調節剤による治療選択肢の拡大や、疾患治療のための新製品のイントロダクションが市場の成長に寄与しています。

新製品の発売と経口薬への傾斜が、同分野の成長を後押しする主な要因となっています。

北米が最大の市場シェアを占めています。北米はバイオジェン、ノバルティスAG、サノフィSAなどの企業にとって最も重要な市場です。そのため、これらの企業は最新の医薬品を優先的に市場に投入しています。

アジア太平洋地域は、多発性硬化症市場において最も速い成長を示しており、その大幅な成長率は、同地域における製薬会社の販売網の強化に起因しています。MS治療に関連する費用の削減を目的とした政府の取り組みが多くの国で実施されるようになっていることが、この地域のMS治療薬需要を促進する重要な要因となっています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の多発性硬化症市場に関する洞察

  • 多発性硬化症市場- 業界スナップショット
  • 多発性硬化症市場力学
    • 促進要因と機会
      • FDAの承認数の増加が市場の成長を促進する
      • ヘルスケアインフラへの投資の急増が市場の成長を促進する
    • 抑制要因と課題
      • 医薬品に関連する高コストが市場の成長を妨げている
  • PESTLE分析
  • 多発性硬化症業界の動向
  • バリューチェーン分析
  • COVID-19感染症の影響分析

第5章 世界の多発性硬化症市場、薬剤タイプ別

  • 主な調査結果
  • イントロダクション
  • 免疫抑制剤
  • 免疫調節因子

第6章 世界の多発性硬化症市場、投与経路別

  • 主な調査結果
  • イントロダクション
  • 注射剤
  • 経口剤

第7章 地域の世界の多発性硬化症市場

  • 主な調査結果
  • イントロダクション
    • 多発性硬化症市場評価、地域、2019-2032年
  • 多発性硬化症市場-北米
    • 北米：多発性硬化症市場、投与経路別、2019～2032年
    • 北米：多発性硬化症市場、薬剤タイプ別、2019-2032年
    • 多発性硬化症市場-米国
    • 多発性硬化症市場- カナダ
  • 多発性硬化症市場- 欧州
    • 欧州：多発性硬化症市場、投与経路別、2019～2032年
    • 欧州：多発性硬化症市場、薬剤タイプ別、2019～2032年
    • 多発性硬化症市場- 英国
    • 多発性硬化症市場- フランス
    • 多発性硬化症市場- ドイツ
    • 多発性硬化症市場- イタリア
    • 多発性硬化症市場- スペイン
    • 多発性硬化症市場- オランダ
    • 多発性硬化症市場- ロシア
  • 多発性硬化症市場- アジア太平洋
    • アジア太平洋地域：多発性硬化症市場、投与経路別、2019～2032年
    • アジア太平洋地域：多発性硬化症市場、薬剤タイプ別、2019～2032年
    • 多発性硬化症市場- 中国
    • 多発性硬化症市場- インド
    • 多発性硬化症市場- マレーシア
    • 多発性硬化症市場- 日本
    • 多発性硬化症市場- インドネシア
    • 多発性硬化症市場- 韓国
  • 多発性硬化症市場-中東およびアフリカ
    • 中東およびアフリカ：多発性硬化症市場、投与経路別、2019～2032年
    • 中東およびアフリカ：多発性硬化症市場、薬剤タイプ別、2019～2032年
    • 多発性硬化症市場- サウジアラビア
    • 多発性硬化症市場- アラブ首長国連邦
    • 多発性硬化症市場- イスラエル
    • 多発性硬化症市場- 南アフリカ
  • 多発性硬化症市場-ラテンアメリカ
    • ラテンアメリカ：多発性硬化症市場、投与経路別、2019～2032年
    • ラテンアメリカ：多発性硬化症市場、薬剤タイプ別、2019-2032年
    • 多発性硬化症市場- メキシコ
    • 多発性硬化症市場- ブラジル
    • 多発性硬化症市場- アルゼンチン

第8章 競合情勢

  • 拡張と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第9章 企業プロファイル

  • Hoffmann-La Roche Ltd.
  • Bayer Healthcare AG
  • Teva Pharmaceuticals
  • GlaxoSmithKline
  • AbbVie Inc.
  • Sonafi Pasteur
  • Pfizer Inc
  • Merck & Company
  • Novartis AG
  • AB Science
  • Opexa
図表

List of Tables

  • Table 1 Global Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 2 Global Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 3 Multiple Sclerosis Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 4 North America: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 5 North America: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 6 U.S.: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 7 U.S.: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 8 Canada: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 9 Canada: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 10 Europe: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 11 Europe: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 12 UK: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 13 UK: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 14 France: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 15 France: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 16 Germany: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 17 Germany: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 18 Italy: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 19 Italy: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 20 Spain: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 21 Spain: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 22 Netherlands: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 23 Netherlands: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 24 Russia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 25 Russia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 26 Asia Pacific: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 27 Asia Pacific: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 28 China: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 29 China: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 30 India: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 31 India: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 32 Malaysia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 33 Malaysia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 34 Japan: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 35 Japan: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 36 Indonesia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 37 Indonesia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 38 South Korea: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 39 South Korea: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 40 Middle East & Africa: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 41 Middle East & Africa: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 42 Saudi Arabia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 43 Saudi Arabia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 44 UAE: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 45 UAE: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 46 Israel: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 47 Israel: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 48 South Africa: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 49 South Africa: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 50 Latin America: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 51 Latin America: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 52 Mexico: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 53 Mexico: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 54 Brazil: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 55 Brazil: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 56 Argentina: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 57 Argentina: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)

List of Figures

  • Figure 1 Global Multiple Sclerosis Market, 2019-2032 (USD Billion)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by Route of Administration
  • Figure 7 Global Multiple Sclerosis Market, by Route of Administration, 2022 & 2032 (USD Billion)
  • Figure 8 Market by Drug type
  • Figure 9 Global Multiple Sclerosis Market, by Drug type, 2022 & 2032 (USD Billion)
  • Figure 10 Multiple Sclerosis Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 11 Strategic Analysis - Multiple Sclerosis Market
目次
Product Code: PM1343

The global multiple sclerosis market size is expected to reach USD 33.57 billion by 2032, according to a new study by Polaris Market Research. The report "Multiple Sclerosis Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Immunosuppressants, Immunomodulators); By Route of Administration; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increased emphasis on research and development (R&D) for the creation of ground-breaking pharmaceuticals by prominent industry participants is credited with the global market's expansion. For instance, Adamas Pharmaceuticals Inc. announced findings from a phase 3 clinical trial evaluating ADS-5102, an investigational amantadine agent designed to treat patients with multiple sclerosis (MS), in December 2020.

Product introductions, escalating governmental efforts to improve treatment and care accessibility, and the rising incidence of multiple sclerosis are anticipated to drive market growth.

The growing global impact of multiple sclerosis is causing increasing concern among healthcare providers and governments. The disease's rising prevalence has compelled governments in a number of countries to take proactive measures, such as developing guidelines and recommendations.

Also, government organizations are launching a variety of awareness campaigns to educate patients about the various treatment options which are available.

For instance, the German Multiple Sclerosis Society runs three to four industries in Germany to help people with Multiple Sclerosis. They organize a World MS Day competition every May 31st with the goal of removing accessibility barriers and extending the support network for those affected by multiple sclerosis.

Monoclonal antibodies are becoming more popular in the treatment of multiple sclerosis. Many companies are committed to developing new drugs for multiple sclerosis by leveraging the potential of these antibodies. Furthermore, global demand for humanized monoclonal antibodies, a common class of immunosuppressive drugs used to treat multiple sclerosis, is increasing. Particularly, Ocrevus, introduced by F. Hoffmann-La Roche Ltd., has emerged as the biggest drug, contributing to a substantial revenue and contributing to the market's continuous growth.

Multiple Sclerosis Market Report Highlights

The immunomodulators segment held the largest revenue share in the multiple sclerosis market. The expansion of immunomodulator treatment options and the introduction of new products for treating the disease is contribute to the growth of the market.

The oral segment is witnessed for the fastest market growth during the forecast period. owing to the launch of new products and the incline towards the oral drugs are the key factors which bolster the growth of the segment.

North America accounted for the largest market share. The north america is the most important market for companies such as Biogen, Novartis AG, and Sanofi SA. As a result, these companies are prioritizing the introduction of their most recent pharmaceuticals in market.

The Asia-Pacific region witnessed for the fastest growth in the multiple sclerosis market, the substantial growth rate is ascribed to the enhanced distribution networks of an pharmaceutical companies in the region. The growing implementation of government initiatives in a number of countries aimed at lowering the costs associated with MS treatment is a key driver driving the region's demand for MS drugs.

The global key market players include Hoffmann-La Roche Ltd., Bayer Healthcare AG, Teva Pharmaceuticals, GlaxoSmithKline, AbbVie, Inc., Sonafi Pasteur, Pfizer Inc., Merck & Company, Novartis AG, AB Science, and Opexa.

Polaris Market Research has segmented the multiple sclerosis market report based on drug type, route of administration and region:

Multiple Sclerosis, Drug Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Immunosuppressants
  • Lemtarda
  • Ocrelizumab
  • Zinbryta
  • Aubagio
  • Immunomodulators
  • Ampyra
  • Capxone
  • Betaseron/Extavia
  • Gilneya
  • Avonex/Plegridy
  • Tyasabri
  • Rebif
  • Teucifidera

Multiple Sclerosis, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

  • Injectable Agents
  • Oral Agents

Multiple Sclerosis, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Multiple Sclerosis Market Insights

  • 4.1. Multiple Sclerosis Market - Industry Snapshot
  • 4.2. Multiple Sclerosis Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rise in the number of FDA approval will drive the growth of the market
      • 4.2.1.2. Surge in the investment for healthcare infrastructure will bolster the growth of the market
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost associated with the drugs hindering the growth of the market
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Multiple Sclerosis Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Multiple Sclerosis Market, by Drug type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Multiple Sclerosis, by Drug type, 2019-2032 (USD Billion)
  • 5.3. Immunosuppressants
    • 5.3.1. Global Multiple Sclerosis Market, by Immunosuppressants, by Region, 2019-2032 (USD Billion)
    • 5.3.2. Lemtarda
      • 5.3.2.1. Global Multiple Sclerosis Market, by Lemtarda, by Region, 2019-2032 (USD Billion)
    • 5.3.3. Ocrelizumab
      • 5.3.3.1. Global Multiple Sclerosis Market, by Ocrelizumab, by Region, 2019-2032 (USD Billion)
    • 5.3.4. Zinbryta
      • 5.3.4.1. Global Multiple Sclerosis Market, by Zinbryta, by Region, 2019-2032 (USD Billion)
    • 5.3.5. Aubagio
      • 5.3.5.1. Global Multiple Sclerosis Market, by Aubagio, by Region, 2019-2032 (USD Billion)
  • 5.4. Immunosuppressants
    • 5.4.1. Global Multiple Sclerosis Market, by Immunosuppressants, by Region, 2019-2032 (USD Billion)
    • 5.4.2 Ampyra
    • 5.4.21. Global Multiple Sclerosis Market, by Ampyra, by Region, 2019-2032 (USD Billion)
    • 5.4.3 Capxone
      • 5.4.3.1. Global Multiple Sclerosis Market, by Capxone, by Region, 2019-2032 (USD Billion)
    • 5.4.4 Betaseron/Extavia
      • 5.4.4.1. Global Multiple Sclerosis Market, by Betaseron/Extavia, by Region, 2019-2032 (USD Billion)
    • 5.4.5 Gilneya
      • 5.4.5.1. Global Multiple Sclerosis Market, by Gilneya, by Region, 2019-2032 (USD Billion)
    • 5.4.6 Avonex/Plegridy
      • 5.4.6.1. Global Multiple Sclerosis Market, by Avonex/Plegridy, by Region, 2019-2032 (USD Billion)
    • 5.4.7 Tyasabri
      • 5.4.7.1. Global Multiple Sclerosis Market, by Tyasabri, by Region, 2019-2032 (USD Billion)
    • 5.4.8 Rebif
      • 5.4.8.1. Global Multiple Sclerosis Market, by Rebif, by Region, 2019-2032 (USD Billion)
    • 5.4.9 Teucifidera
    • 5.4.91. Global Multiple Sclerosis Market, by Teucifidera, by Region, 2019-2032 (USD Billion)

6. Global Multiple Sclerosis Market, by Route of Administration

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • 6.3. Injectable Agents
    • 6.3.1. Global Multiple Sclerosis Market, by Injectable Agents, by Region, 2019-2032 (USD Billion)
  • 6.4. Oral Agents
    • 6.4.1. Global Multiple Sclerosis Market, by Oral Agents, by Region, 2019-2032 (USD Billion)

7. Global Multiple Sclerosis Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Multiple Sclerosis Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 7.3. Multiple Sclerosis Market - North America
    • 7.3.1. North America: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
    • 7.3.2. North America: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.3.3. Multiple Sclerosis Market - U.S.
      • 7.3.3.1. U.S.: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.3.3.2. U.S.: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.3.4. Multiple Sclerosis Market - Canada
      • 7.3.4.1. Canada: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.3.4.2. Canada: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • 7.4. Multiple Sclerosis Market - Europe
    • 7.4.1. Europe: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
    • 7.4.2. Europe: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.4.3. Multiple Sclerosis Market - UK
      • 7.4.3.1. UK: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.4.3.2. UK: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.4.4. Multiple Sclerosis Market - France
      • 7.4.4.1. France: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.4.4.2. France: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.4.5. Multiple Sclerosis Market - Germany
      • 7.4.5.1. Germany: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.4.5.2. Germany: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.4.6. Multiple Sclerosis Market - Italy
      • 7.4.6.1. Italy: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.4.6.2. Italy: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.4.7. Multiple Sclerosis Market - Spain
      • 7.4.7.1. Spain: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.4.7.2. Spain: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.4.8. Multiple Sclerosis Market - Netherlands
      • 7.4.8.1. Netherlands: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.4.8.2. Netherlands: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.4.9. Multiple Sclerosis Market - Russia
      • 7.4.9.1. Russia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.4.9.2. Russia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • 7.5. Multiple Sclerosis Market - Asia Pacific
    • 7.5.1. Asia Pacific: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
    • 7.5.2. Asia Pacific: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.5.3. Multiple Sclerosis Market - China
      • 7.5.3.1. China: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.5.3.2. China: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.5.4. Multiple Sclerosis Market - India
      • 7.5.4.1. India: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.5.4.2. India: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.5.5. Multiple Sclerosis Market - Malaysia
      • 7.5.5.1. Malaysia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.5.5.2. Malaysia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.5.6. Multiple Sclerosis Market - Japan
      • 7.5.6.1. Japan: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.5.6.2. Japan: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.5.7. Multiple Sclerosis Market - Indonesia
      • 7.5.7.1. Indonesia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.5.7.2. Indonesia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.5.8. Multiple Sclerosis Market - South Korea
      • 7.5.8.1. South Korea: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.5.8.2. South Korea: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • 7.6. Multiple Sclerosis Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
    • 7.6.2. Middle East & Africa: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.6.3. Multiple Sclerosis Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.6.4. Multiple Sclerosis Market - UAE
      • 7.6.4.1. UAE: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.6.4.2. UAE: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.6.5. Multiple Sclerosis Market - Israel
      • 7.6.5.1. Israel: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.6.5.2. Israel: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.6.6. Multiple Sclerosis Market - South Africa
      • 7.6.6.1. South Africa: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.6.6.2. South Africa: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • 7.7. Multiple Sclerosis Market - Latin America
    • 7.7.1. Latin America: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
    • 7.7.2. Latin America: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.7.3. Multiple Sclerosis Market - Mexico
      • 7.7.3.1. Mexico: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.7.3.2. Mexico: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.7.4. Multiple Sclerosis Market - Brazil
      • 7.7.4.1. Brazil: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.7.4.2. Brazil: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.7.5. Multiple Sclerosis Market - Argentina
      • 7.7.5.1. Argentina: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.7.5.2. Argentina: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Hoffmann-La Roche Ltd.
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Bayer Healthcare AG
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Teva Pharmaceuticals
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. GlaxoSmithKline
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. AbbVie Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Sonafi Pasteur
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Pfizer Inc
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Merck & Company
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Novartis AG
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. AB Science
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Opexa
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development